Could a Pre-Treatment drug make CAR-T therapy more effective for tough lymphomas?
NCT ID NCT04855253
First seen Jan 15, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This study tests whether adding a drug called E7777 before standard CAR-T cell therapy can help people with relapsed or hard-to-treat large B-cell lymphoma. About 30 adults will receive E7777 followed by chemotherapy and an approved CAR-T product. The goal is to find the safest dose and see if it improves cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.